Brief: Pharnext Halts Alzheimer's Disease Drug Candidate PXT864 Development
14/02/2023 07:34
Feb 14 (Reuters) - Pharnext SA PHARN.PA :
* REFOCUSES ITS CLINICAL STUDY PROGRAMS ON PXT3003 TO
OPTIMIZE THE
ALLOCATION OF ITS FINANCIAL RESOURCES
* RESULTS OF ITS PIVOTAL PHASE III CLINICAL STUDY, THE
PREMIER
TRIAL, EXPECTED IN Q4 2023
* DECIDED TO HALT THE DEVELOPMENT OF ITS DRUG CANDIDATE
PXT864 IN
ALZHEIMER'S DISEASE
* PXT864: STUDY RESULTS SO FAR ARE NOT SUFFICIENT TO PLAN
COMMERCIAL USE IN SHORT AND MID-TERM
Source text for Eikon: ID:nACT78558
Further company coverage: PHARN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development